R3Mab

R3Mab is a **monoclonal antibody** that selectively targets fibroblast growth factor receptor 3 (FGFR3). It functions as a neutralizing antibody binding specifically to FGFR3, blocking the interaction of the receptor with its ligands FGF1 and FGF9, inhibiting receptor dimerization, and thereby antagonizing FGFR3 signaling. This results in inhibition of downstream signaling pathways such as phosphorylation of FRS2α and MAPK, which are essential for cell proliferation in FGFR3-driven tumors. R3Mab has demonstrated potent antitumor activity in preclinical models of **bladder carcinoma** and **multiple myeloma** by inhibiting both wild-type and mutant FGFR3, including the S249C mutation. Its mechanism includes both direct antagonism of FGFR3 and antibody-dependent cell-mediated cytotoxicity (ADCC). In vivo, repeated dosing of R3Mab was well tolerated in mice with no discernible toxicity. The antibody is considered a candidate for the treatment of tumors overexpressing or featuring activating mutations of FGFR3[1][2][3][5].

Brand names

R3MabR-3MabR 3Mab

Other names

R3MabR-3MabR 3Mab